Previous 10 | Next 10 |
home / stock / esaly / esaly news
Eisai to Divest Rights for Muscle Relaxant Myonal, Vertigo, and Equilibrium Disturbance Treatment Merislon in Asia to DKSH TOKYO, Nov 7, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has entered into an agreement to divest its rights for muscle relaxant Myona...
Eisai's Sales Subsidiary Collaborates with Thai Life Insurance to Support Access to Treatments for Dementia, Including Alzheimer's Disease, in Thailand TOKYO, Nov 4, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that its Thai sales subsidiary Eisai (Thailand) Marketi...
Summary The Clinical Trials on Alzheimer’s Conference will take place from November 29, 2022 to December 2, 2022. Representatives of several listed companies will present data, including Eisai, Anavex, BioVie, Athira Pharma, Cassava Sciences and NervGen. This conference...
Eisai Satisfies All-case Study Requirement for Antiepileptic Agent Inovelon TOKYO, Nov 2, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has received notification from Japan's Ministry of Health, Labour, and Welfare (MHLW) that the "all-case study" specified p...
Eisai Announces Plans to Submit Application for Partial Change to Label for Dosage and Administration of Aricept for Treatment of Dementia with Lewy Bodies Based on Results of Drug Reexamination TOKYO, Nov 2, 2022 - (JCN Newswire) - Eisai Co., Ltd. announced today that it has ...
Summary Biogen appears set to obtain approval of a 2nd Alzheimer's drug. Lecanemab is far better received by the market with total peak sales forecasted at up to $14 billion with Biogen sharing 50% of the profits. The earnings potential of the Alzheimer's franchise places the ...
Summary Biogen remains a financially cheap, unloved Big Pharma name with a number of promising drugs under development. The latest positive readout on LECANEMAB, its second Alzheimer's drug likely to get FDA approval, could increase EPS dramatically in future years. Strong ups...
Summary Athira Pharma’s stock has sold off some months ago on its Alzheimer’s drug candidate Fosgonimeton not meeting a primary endpoint in a randomized Phase 2 trial. The monotherapy arm did show remarkable efficacy, which appears stronger than 27% slowing of cognit...
Summary Alzheimer's Disease is one of the largest unmet medical needs. Today, there are 139 drugs in clinical trials for Alzheimer's. In this piece, we dive into 8 of the most impactful and promising trials. Introduction Alzheimer's disease is the largest unmet...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Reportedly, Biogen (NASDAQ: BIIB ) and Japanese pharmaceutical company Eisai (OTCMKTS: ESALY ) achieved positive test results for their Alzheimer’s disease treatment. As you might expect, BIIB...
News, Short Squeeze, Breakout and More Instantly...
Eisai Co. Ltd. ADR Company Name:
ESALY Stock Symbol:
OTCMKTS Market:
Eisai's Initiatives for Developing New Medicines for Neglected Tropical Diseases and Malaria and Commitment for Funding to the 3rd Phase of Global Health Innovative Technology Fund Activities TOKYO, May 25, 2023 - (JCN Newswire) - Eisai Co., Ltd. has announced that it will grant a t...
Eisai Delivers New Data and Highlights Continued Progress of Oncology Portfolio and Pipeline at ASCO 2023 TOKYO, May 24, 2023 - (JCN Newswire) - Eisai Co., Ltd. announced today the presentation of research across various types of cancer from its oncology portfolio and pipeline durin...
Health Canada Accepts New Drug Submission for Lecanemab as Treatment for Early Alzheimer's Disease TOKYO and CAMBRIDGE, Mass., May 16, 2023 - (JCN Newswire) - Eisai Co., Ltd. and Biogen Inc. announced today that Health Canada has accepted a New Drug Submission (NDS) for lecanemab (b...